

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hurvitz Eli</u> (Last) (First) (Middle) <u>C/O ORTHODONTIX, 2 SNUTIT ST</u> <u>SCIENCE PARK, POB 455</u> (Street) <u>CARMIEL,</u> <u>21000</u> <u>ISRAEL</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ORTHODONTIX INC [ORTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>12/31/2006</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/31/2006		A		2,886,447 ⁽¹⁾	A	(1)	2,886,447	I	By Partnership

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$0.001	12/31/2006		A		1,616,100		(2)	03/16/2010	Common Stock	1,616,100	(3)	1,616,100	I	By Partnership
Stock Options (Right to Buy)	\$0.001	12/31/2006		A		1,768,402		(4)	03/16/2010	Common Stock	1,768,402	(5)	3,384,502	I	By Partnership

Explanation of Responses:

- Received in exchange for 47,256 ordinary shares of Protalix Ltd. (Protalix) in connection with the merger (the Merger) of Protalix into a wholly-owned subsidiary of Orthodontix, Inc. (Orthodontix). The shares acquired consist of 1,378,278 shares of Common Stock held by Pontifax (Cayman) L.P. and 1,508,169 of Common Stock held by Pontifax (Israel) L.P. Mr. Hurvitz disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- All shares of Common Stock underlying the options have vested prior to the date of the transaction.
- Received in connection with the Merger in exchange for options to acquire 26,710 ordinary shares of Protalix. 771,688 of the shares of Common Stock underlying the options are held by Pontifax (Cayman) L.P., and 844,412 of the shares of Common Stock underlying the options are held by Pontifax (Israel) L.P. Mr. Hurvitz disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- 50% of the options vested on January 1, 2007, and an additional 10% of the options will vest at the end of each three-month period thereafter.
- Received in connection with the Merger in exchange for options to acquire 28,700 ordinary shares of Protalix. 844,412 of the shares of Common Stock underlying the options are held by Pontifax (Cayman) L.P., and 923,990 of the shares of Common Stock underlying the options are held by Pontifax (Israel) L.P. Mr. Hurvitz disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.

David Aviezer, Power of Attorney 01/04/2007

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints David Aviezer, Ph.D., MBA and Yossi Maimon the undersigned's true and lawful attorney-in-fact to: (i) execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended and the rules thereunder in connection with the undersigned's holdings of and transactions in securities issued by Orthodontix, Inc., a Florida corporation (the "Company"); (ii) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any required stock exchange or similar authority, including the American Stock Exchange and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of December 12, 2006.

/s/ Eli Hurvitz

Name: Eli Hurvitz